2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists: Structure activity relationships of the 2-oxy pyridine C-region

European Journal of Medicinal Chemistry

Volumn 64, Issue , 2013, Pages 589-602

  Thorat, Shivaji A ^a   Kang, Dong Wook ^a,e   Ryu, Hyungchul ^a   Kim, Myeong Seop ^a   Kim, Ho Shin ^a   Ann, Jihyae ^a   Ha, Taehwan ^a   Kim, Sung Eun ^a   Son, Karam ^b   Choi, Sun ^b   Blumberg, Peter M ^c   Frank, Robert ^d   Bahrenberg, Gregor ^d   Schiene, Klaus ^d   Christoph, Thomas ^d   Lee, Jeewoo ^a  

^a Seoul National University   (South Korea)

^b Ewha Womans University   (South Korea)

^c NATIONAL CANCER INSTITUTE   (United States)

^d GRÜNENTHAL GMBH   (Germany)

^e Catholic University of Daegu   (South Korea)

Author keywords

Analgesic; Capsaicin; Molecular modeling; TRPV1 antagonists

Indexed keywords

CAPSAICIN; CARBON; FORMALDEHYDE; HYDROGEN; N [[2 (2 ETHOXYETHOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (2 METHOXYETHOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (2 PHENOXYETHOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (2,6 DIMETHYLHEPTAN 4 YLOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (3 ETHOXYPROPOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (3 METHOXYPROPOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (3,3 DIMETHYLBUTOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (BUT 2 EN 1 YLOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (HEPTAN 4 YLOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (NONAN 5 YLOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (PENT 2 EN 1 YLOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 (PENTAN 3 YLOXY) 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 BUTOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 CYCLOBUTOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 CYCLOHEXYLOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 CYCLOPENTYLOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 ETHOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 HEXYLOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 ISOBUTOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 ISOPENTYLOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 ISOPROPOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 METHOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 PENTYLOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL] METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; N [[2 PROPOXY 6 (TRIFLUOROMETHYL)PYRIDIN 3 YL]METHYL] 2 [3 FLUORO 4 (METHYLSULFONAMIDO)PHENYL]PROPANAMIDE; PROPIONAMIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; DRUG ANTAGONISM; DRUG POTENCY; HYDROGEN BOND; HYDROPHOBICITY; LIPOPHILICITY; MOLECULAR MODEL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

BENZENEACETAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRPV CATION CHANNELS;

EID: 84879017091     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.04.003     Document Type: Article

References (22)

1. A. Szallasi, and P.M. Blumberg Vanilloid (Capsaicin) receptors and mechanisms Pharmacol. Rev. 51 1999 159 211
2. M. Tominaga, M.J. Caterina, A.B. Malmberg, T.A. Rosen, H. Gilbert, K. Skinner, B.E. Raumann, A.I. Basbaum, and D. Julius The cloned capsaicin receptor integrates multiple pain-producing stimuli Neuron 21 1998 531 543
3. M.J. Caterina, M.A. Schumacher, M. Tominaga, T.A. Rosen, J.D. Levine, and D. Julius The capsaicin receptor: a heat-activated ion channel in the pain pathway Nature 389 1997 816 824
4. P.M. Zygmunt, J. Petersson, D.A. Andersson, H.-H. Chuang, M. Sorgard, V. Di Marzo, D. Julius, and E.D. Hogestatt Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide Nature 400 1999 452 457
5. S.W. Hwang, H. Cho, J. Kwak, S.Y. Lee, C.J. Kang, J. Jung, S. Cho, K.H. Min, Y.G. Suh, D. Kim, and U. Oh Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances Proc. Natl. Acad. Sci. U. S. A. 97 2000 6155 6160
6. C.S.J. Walpole, and R. Wrigglesworth Capsaicin in the Study of Pain 1993 Academic Press San Diego, CA 63 82
7. G. Appendino, and A. Szallasi Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine Life Sci. 60 1997 681 696
8. A. Szallasi, F. Cruz, and P. Geppetti TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol. Med. 12 2006 545 554
9. A. Szallasi, and M. Sheta Targeting TRPV1 for pain relief: limits, losers and laurels Expert Opin. Investig. Drugs 21 2012 1351 1369
10. J. Szolcsányi, and Z. Sándor Multisteric TRPV1 nocisensor: a target for analgesics Trend Pharmacol. Sci. 33 2012 646 655
11. E.A. Voight, and M.E. Kort Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature Exp. Opin. Ther. Pat. 20 2010 1 16
12. J. Lazar, L. Gharat, N. Khairathkar-Joshi, P.M. Blumberg, and A. Szallasi Screening TRPV1 antagonists for the treatment of pain: lessons learned over a decade Expert Opin. Drug Discovery 4 2009 159 180
13. M.J. Gunthorpe, and B.A. Chizh Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway Drug Discov. Today 14 2009 56 67
14. G.Y. Wong, and N.R. Gavva Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks Brain Res. Rev. 60 2009 267 277
15. P.R. Kym, M.E. Kort, and C.W. Hutchins Analgesic potential of TRPV1 antagonists Biochem. Pharmacol. 78 2009 211 216
16. M.S. Kim, H. Ryu, D.W. Kang, S.-H. Cho, S. Seo, Y.S. Park, M.-Y. Kim, E.J. Kwak, Y.S. Kim, R.S. Bhondwe, H.S. Kim, S.-G. Park, K. Son, S. Choi, I. DeAndrea-Lazarus, L.V. Pearce, P.M. Blumberg, R. Frank, G. Bahrenberg, H. Stockhausen, B.Y. Kögel, K. Schiene, T. Christoph, and J. Lee 2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3- ylmethyl) C-region J. Med. Chem. 55 2012 8392 8408
17. Y.S. Kim, M.-J. Kil, S.-U. Kang, H. Ryu, M.S. Kim, Y. Cho, R.S. Bhondwe, S.A. Thorat, W. Sun, K. Liu, J.H. Lee, S. Choi, L.V. Pearce, V.A. Pavlyukovets, M.A. Morgan, R. Tran, J. Lazar, P.M. Blumberg, and J. Lee N-4-t-Butylbenzyl 2-(4-methylsulfonylaminophenyl)propanamide TRPV1 antagonists: structure-activity relationships in the A-region Bioorg. Med. Chem. 20 2012 215 224
18. H. Ryu, M.-K. Jin, S.-U. Kang, S.Y. Kim, D.W. Kang, J. Lee, L.V. Pearce, V.A. Pavlyukovets, M.A. Morgan, R. Tran, A. Toth, D.J. Lundberg, and P.M. Blumberg Stereospecific high-affinity TRPV1 antagonists: chiral N-(2-benzyl-3-pivaloyloxypropyl) 2-[4-(methylsulfonylamino)phenyl]propionamide analogues J. Med. Chem. 51 2008 57 67
19. R.M. Reilly, H.A. McDonald, P.S. Puttfarcken, S.K. Joshi, L. Lewis, M. Pai, P.H. Franklin, J.A. Segreti, T.R. Neelands, P. Han, J. Chen, P.W. Mantyh, J.R. Ghilardi, T.M. Turner, E.A. Voight, J.F. Daanen, R.G. Schmidt, A. Gomtsyan, M.E. Kort, C.R. Faltynek, and P.R. Kym Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature J. Pharmacol. Exp. Ther. 342 2012 416 428
20. D. Dubuisson, and S.G. Dennis The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats Pain 4 1977 161 174
21. J.H. Lee, Y. Lee, H. Ryu, D.W. Kang, J. Lee, J. Lazar, L.V. Pearce, V.A. Pavlyukovets, P.M. Blumberg, and S. Choi Structural insights into transient receptor potential vanilloid type 1 (TRPV1) from homology modeling, flexible docking, and mutational studies J. Comput. Aided Mol. Des. 25 2011 317 327
22. M. Zimmermann Ethical guidelines for investigations of experimental pain in conscious animals Pain 16 1983 109 110